enGene Holdings Inc. (NASDAQ:ENGN) Shares Bought by Fcpm Iii Services B.V.

Fcpm Iii Services B.V. boosted its holdings in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 11.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,632,561 shares of the company's stock after purchasing an additional 954,610 shares during the quarter. enGene makes up about 10.9% of Fcpm Iii Services B.V.'s investment portfolio, making the stock its 3rd largest holding. Fcpm Iii Services B.V. owned about 21.78% of enGene worth $64,057,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Franklin Resources Inc. boosted its position in enGene by 48.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock valued at $7,854,000 after purchasing an additional 389,918 shares during the period. Vontobel Holding Ltd. bought a new stake in enGene in the fourth quarter valued at $69,000. Blue Owl Capital Holdings LP lifted its stake in enGene by 3.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock valued at $21,014,000 after buying an additional 101,006 shares during the last quarter. Jane Street Group LLC bought a new stake in enGene in the fourth quarter valued at $93,000. Finally, Cubist Systematic Strategies LLC lifted its stake in enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock valued at $102,000 after buying an additional 2,080 shares during the last quarter. Institutional investors and hedge funds own 64.16% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ENGN shares. HC Wainwright restated a "buy" rating and set a $25.00 price objective on shares of enGene in a research note on Tuesday, March 11th. Morgan Stanley cut their price objective on shares of enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 11th. Piper Sandler started coverage on shares of enGene in a research note on Tuesday, February 18th. They set an "overweight" rating and a $26.00 price objective on the stock. UBS Group cut shares of enGene from a "buy" rating to a "neutral" rating and cut their price objective for the company from $34.00 to $7.00 in a research note on Friday, February 14th. Finally, JMP Securities reissued a "market outperform" rating and issued a $18.00 price objective on shares of enGene in a research note on Tuesday, April 29th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, enGene currently has a consensus rating of "Buy" and an average target price of $23.29.

enGene Stock Up 4.5%

Shares of ENGN stock traded up $0.13 on Wednesday, reaching $3.01. 94,948 shares of the company's stock traded hands, compared to its average volume of 128,315. enGene Holdings Inc. has a 12-month low of $2.65 and a 12-month high of $14.24. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The company has a market capitalization of $153.44 million, a P/E ratio of -5.19 and a beta of -0.36. The business's 50 day moving average price is $4.30 and its two-hundred day moving average price is $6.19.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.